PDE9A Promotes Calcium-Handling Dysfunction in Right Heart Failure via cGMP–PKG Pathway Suppression: A Mechanistic and Therapeutic Review
International Journal of Molecular Sciences · 2025
DOI: 10.3390/ijms26136361 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Spencer Thatcher und 4 weiteren Autor:innen. Beteiligte Einrichtung: Kirk Kerkorian School of Medicine at UNLV, Las Vegas, NV 89106, USA. Hauptthemen laut MEDLINE: Heart Failure, Calcium, Cyclic GMP, Cyclic GMP-Dependent Protein Kinases. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: School of Medicine Library Open Article Fund.
Themen: Herzinsuffizienz
Abstract (Originalsprache)
Right heart failure (RHF) is a major cause of morbidity and mortality, often resulting from pulmonary arterial hypertension and characterized by impaired calcium (Ca2+) handling and maladaptive remodeling. Phosphodiesterase 9A (PDE9A), a cGMP-specific phosphodiesterase, has been proposed as a potential contributor to RHF pathogenesis by suppressing the cardioprotective cGMP–PKG signaling pathway—a conclusion largely extrapolated from left-sided heart failure models. This review examines existing evidence regarding PDE9A’s role in RHF, focusing on its effects on intracellular calcium cycling, fibrosis, hypertrophy, and contractile dysfunction. Data from preclinical models demonstrate that pathological stress upregulates PDE9A expression in cardiomyocytes, leading to diminished PKG activation, impaired SERCA2a function, RyR2 instability, and increased arrhythmogenic Ca2+ leak. Pharmacological or genetic inhibition of PDE9A restores cGMP signaling, improves calcium handling, attenuates hypertrophic and fibrotic remodeling, and enhances ventricular compliance. Early-phase clinical studies in heart failure populations suggest that PDE9A inhibitors are well tolerated and effectively augment cGMP levels, although dedicated trials in RHF are still needed. Overall, these findings indicate that targeting PDE9A may represent a promising therapeutic strategy to improve outcomes in RHF by directly addressing the molecular mechanisms underlying calcium mishandling and myocardial remodeling.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Kirk Kerkorian School of Medicine at UNLV, Las Vegas, NV 89106, USA.
- Department of Internal Medicine, Kirk Kerkorian School of Medicine at UNLV, Las Vegas, NV 89106, USA.
ORCID-Profile: Abu-Bakr Ahmed
Förderung
- School of Medicine Library Open Article Fund
Zitieren
APA
Thatcher, S., Khalid, A., Ahmed, A. B., Gill, R., & Kia, A. (2025). PDE9A Promotes Calcium-Handling Dysfunction in Right Heart Failure via cGMP–PKG Pathway Suppression: A Mechanistic and Therapeutic Review. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26136361
Vancouver
Thatcher S, Khalid A, Ahmed AB, Gill R, Kia A. PDE9A Promotes Calcium-Handling Dysfunction in Right Heart Failure via cGMP–PKG Pathway Suppression: A Mechanistic and Therapeutic Review. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26136361
BibTeX
@article{Thatcher2025,
author = {Thatcher, Spencer and Khalid, Arbab and Ahmed, Abu-Bakr and Gill, Randeep and Kia, Ali},
title = {PDE9A Promotes Calcium-Handling Dysfunction in Right Heart Failure via cGMP–PKG Pathway Suppression: A Mechanistic and Therapeutic Review},
journal = {International Journal of Molecular Sciences},
year = {2025},
doi = {10.3390/ijms26136361}
}
EUVIMED